fluorescent ligands
19 July 2023
Traditional pharmacological mechanisms leave a significant part of the genome ‘undruggable’, due to the inability to induce or block their activity using agonists and antagonists. Thanks […]
13 July 2023
Celtarys expands its presence in the GPCR field, developing new applications in collaboration agreement with Nanotemper, a company devoted to the development of innovative instruments for […]
27 January 2023
WHY IS IMPORTANT TO CONSIDER MULTIPLE ASSAY TYPES FOR TARGETS CHARACTERIZATION? Usually, in the identification of new drug-like molecules for a target of interest it is […]
26 January 2023
Custom synthesis service for fluorescent ligands Celtarys provides custom chemical development services, specifically for the identification of a broad range of robust and complex fluorescent ligands […]
18 November 2022
Our portfolio of #GPCR#fluorescent ligands is growingWe have just added to our catalogue two more fluorescent ligands for the α1-Adrenergic receptor, CELT-130 and CELT-133. α1-Adrenergic receptors play a vital role in the regulation of […]
26 July 2022
The ONCOMET group from the Health Research Institute of Santiago led by Dr. Miguel Abal has published an interesting article showing tumor and stromal-specific genetic signatures […]